EGFR exon 19 deletion + KRAS mutation
|
NSCLC
|
EGFR exon 19 deletion + KRAS mutation
|
NSCLC
|
erlotinib Sensitive: C3 – Early Trials
|
erlotinib Sensitive: C3 – Early Trials
|
EGFR exon 19 deletion + KRAS mutation
|
NSCLC
|
EGFR exon 19 deletion + KRAS mutation
|
NSCLC
|
gefitinib Sensitive: C3 – Early Trials
|
gefitinib Sensitive: C3 – Early Trials
|